Caribou Biosciences Inc (CRBU)vsEli Lilly and Company (LLY)
CRBU
Caribou Biosciences Inc
$1.50
+2.74%
HEALTHCARE · Cap: $161.66M
LLY
Eli Lilly and Company
$1,115.86
-0.49%
HEALTHCARE · Cap: $1.02T
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 644808% more annual revenue ($72.25B vs $11.20M). LLY leads profitability with a 35.0% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 76/100 (B+).
CRBU
Avoid25
out of 100
Grade: F
LLY
Strong Buy76
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+44.6%
Fair Value
$2.87
Current Price
$1.50
$1.37 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Areas to Watch
1.9% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 32.0x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : CRBU
The strongest argument for CRBU centers on Price/Book, Debt/Equity.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : CRBU
The primary concerns for CRBU are Revenue Growth, EPS Growth, Market Cap.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, Debt/Equity, P/E Ratio. A P/E of 41.8x leaves little room for execution misses.
Key Dynamics to Monitor
CRBU profiles as a value stock while LLY is a growth play — different risk/reward profiles.
CRBU carries more volatility with a beta of 2.37 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 25/100), backed by strong 35.0% margins and 55.5% revenue growth. CRBU offers better value entry with a 44.6% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Caribou Biosciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Caribou Biosciences Inc. is a pioneering biotechnology firm specializing in genome editing through its proprietary CRISPR technology, aimed at developing transformative therapies for genetic disorders and oncology. With a robust and diversified pipeline addressing significant unmet medical needs, the company is well-positioned to lead advancements in precision medicine. Caribou's strategic collaborations and unwavering commitment to research excellence underpin its mission to revolutionize treatment paradigms and improve patient outcomes, establishing its foothold as a key player in the biopharmaceutical sector.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?